OncoMatch/Clinical Trials/NCT03331601
Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients
Is NCT03331601 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 68GaNOTA-Anti-HER2 VHH1 for carcinoma.
Treatment: 68GaNOTA-Anti-HER2 VHH1 — This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative cancer will be included and the uptake in their lesions will be compared. Optional 68-GaNOTA-Anti-HER2 VHH1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Allowed: HER2 (ERBB2) potentially HER2-positive
Patients with potentially HER2-positive cancer. Either a HER2 staining should have been done in standard of care, or sufficient tissue should be available for HER2-staining for study purpose.
Disease stage
Metastatic disease required
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify